

Finance Report


January 17, 2012

Financial Highlights

As at Nov. 30, 2011

- YTD (July-Nov '11) OpEx: \$4.85mm
 - Prior period (July-Nov '10): \$4.34mm
- Grant disbursements YTD: \$88.8mm
 - Amount is net of Geron repayment
 - Prior period: \$84.8mm
- Available bond cash: \$203.2mm
 - Also net of Geron repayment

Note: Numbers are preliminary and unaudited




Operating Expense Detail

<i>Dollars in 000s</i>	Jul-Nov 2011	Jul-Nov 2010	Variance
Employee Exp.	\$3,632	\$3,172	14%
Contracting	405	470	-14%
Grant Reviews	103	154	-33%
Travel	111	83	35%
IT	225	276	-18%
ICOC	11	17	-33%
Scientific Meetings	259	94	176%
Office & General Exp.	102	70	45%
Total	\$4,848	\$4,335	12%


Major operating expense variance drivers:

- Increase from 46 to 50 FTEs and merit adjustments
- Timing for contracting; grant reviews; ICOC
- Grantee meeting Sept. 2011; World Stem Cell Oct. 2011

Notes: Numbers are preliminary and unaudited. Only "Employee Exp." accurately reflects costs in the period; posting of all other expense categories lags significantly.



Achieving 3% + 3% Expense Cap



Key Assumptions:

- FY11/12 is \$1mm under budget; FY12/13 is \$1mm lower than FY11/12
- Expense growth of 3% p.a. through FY17/18; gradual decline to FY20/21

Considerations:

- Small savings (or expenses) compound 10x over the coming decade
- Historical expense growth has been greater than 3%
- FY12/13 budget focus on “Must Have” expenses

